Morning Dhukka- I have spent some time looking into this and...

Morning Dhukka- I have spent some time looking into this and contacted the company. They were quick to answer as they have been folowing this FDA approval with interest.

Im am advised that these new classes of drugs such as once a week injections for Diabetes Type 2 patients are not a competitive threat at all.

They are an ENORMOUS OPPORTUNITY for POH.

Since these are in fact NEW DRUGS- ( and not new Delivery Platforms) - POH can delivery them transdermally via their patented TPM patch.

Exenatide (Byetta is the Brand name) and these other new drugs being developed for Diabetics are in fact much smaller molecules than insulin. They are therefore much easier to deliver transdermally than insulin !

How exciting is that????

Further POH has the opportinity to create a blend of say Insulin and Exenatide for patch delivery- which can majke for easier delivery and eliminate the side effects and as a result - create a new POH Super Drug to combat and manage Diabetes which can be delivered by TPM patch, gel or oral.


Awesome? You bet

KC